Gene transfer vectors targeted to human prostate cancer : do we need better preclinical testing systems?

Maitland, Norman, Chambers, Karen F., Georgopoulos, Lindsay, Simpson-Holley, Martha, Leadley, Regina, Evans, Helen, Essand, Magnus, Danielsson, Angelika, van Weerden, Wytske, de Ridder, Corrina, Kraaij, Robert, & Bangma, Chris H. (2010) Gene transfer vectors targeted to human prostate cancer : do we need better preclinical testing systems? Human Gene Therapy, 21(7), pp. 815-827.

View at publisher

Abstract

Destruction of cancer cells by genetically modified viral and nonviral vectors has been the aim of many research programs. The ability to target cytotoxic gene therapies to the cells of interest is an essential prerequisite, and the treatment has always had the potential to provide better and more long-lasting therapy than existing chemotherapies. However, the potency of these infectious agents requires effective testing systems, in which hypotheses can be explored both in vitro and in vivo before the establishment of clinical trials in humans. The real prospect of off-target effects should be eliminated in the preclinical stage, if current prejudices against such therapies are to be overcome. In this review we have set out, using adenoviral vectors as a commonly used example, to discuss some of the key parameters required to develop more effective testing, and to critically assess the current cellular models for the development and testing of prostate cancer biotherapy. Only by developing models that more closely mirror human tissues will we be able to translate literature publications into clinical trials and hence into acceptable alternative treatments for the most commonly diagnosed cancer in humans.

Impact and interest:

6 citations in Scopus
Search Google Scholar™
5 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

188 since deposited on 19 Dec 2012
7 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 55861
Item Type: Journal Article
Refereed: Yes
Keywords: Prostate, Cancer, Adenovirus
DOI: 10.1089/hum.2009.210
ISSN: 1557-7422
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Cell Biology (111201)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (111204)
Divisions: Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2010 Mary Ann Liebert
Deposited On: 19 Dec 2012 06:45
Last Modified: 30 Jun 2014 19:49

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page